LGBTQ Nation article highlights PAN’s clinical trials initiative

The PAN Foundation’s recent survey revealed that 65% of LGBTQ+ respondents expressed a strong willingness to participate in clinical trials.

When asked why they have not participated, 80% of LGBTQ+ individuals report that they’ve simply never been asked to consider clinical trials. 

PAN’s Chief Diversity & Health Equity Officer, Kim Baich, penned an article for LGBTQ Nation for Transgender Awareness Week that examines the underrepresentation of transgender and nonbinary individuals in clinical trials. Fewer than 1% of clinical trials in the United States include transgender or nonbinary patients. In her call-to-action to researchers, healthcare providers, and policymakers to bridge this gap in inclusion, Baich writes, “If you aim to serve the health of the public, you must ensure that clinical trials include transgender and nonbinary patients.” Private companies, nonprofits, and pharmaceutical firms play a vital role in setting active goals to increase representation.

Baich also highlighted PAN’s Opening Doors to Clinical Trials initiative, which provides educational resources, the clinical trial support of ComPANion Access Navigators to help people overcome barriers like transportation and costs related to other basic needs, as well as the TrialFinder tool to locate clinical trials.